News

MAT2501 is an orally-administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic agent amikacin which may be used to treat different types of multidrug-resistant bacteria, including NTM and

The company also announced that the KRAS mutant NSCLC arm will not advance to the second stage. The rationale for these decisions is based on safety and efficacy

The active IND now allows the Company to initiate its planned Phase 3 program for ZX008. Zogenix president and CEO Stephen Farr said: "We are pleased to have

The study is being conducted at The University of Texas MD Anderson Cancer Center and is being led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical

Acute kidney injury (AKI) is a serious medical condition characterized by an abrupt loss of kidney function. AKI is estimated to affect up to 18 percent of hospital

The Wall Street Journal had recently reported that AstraZeneca was looking to acquire Acerta for over $5bn to secure access to its experimental blood cancer drug, acalabrutinib. AstraZeneca

Shopfloor-Online is a well-established, web-based product that has already been installed with hundreds of customers in different sectors across the world and the creation of the Lifescience edition

In the pivotal studies, Alecensa shrank tumors in up to 44 percent of people with ALK-positive NSCLC who progressed on crizotinib (objective response rate [ORR] of 38 percent

The proposed study, which will enroll approximately 75 patients, is projected to launch in Canada in Q2 2016. XBiotech medical director Michael Stecher said, "This program represents the